» Articles » PMID: 34827343

The Impact of the SARS-Cov2 Pandemic on a Persuasive Educational Antimicrobial Stewardship Program in a University Hospital in Southern Italy: A Pre-Post Study

Overview
Specialty Pharmacology
Date 2021 Nov 27
PMID 34827343
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: We evaluated the effect of the pandemic on the disruption of a persuasive educational antimicrobial stewardship program (ASP) conducted in a university hospital in southern Italy.

Methods: In March 2020, the ASP, which began in January 2017 and was carried out at different times in 10 wards, was stopped due to the COVID-19 pandemic. We conducted an observational study with interrupted time series analysis to compare the antibiotic consumption and costs, average length of hospital stay and in-hospital mortality between 12 months before and 9 months after the interruption.

Results: Four medical, four surgical wards and two ICUs were included in the study, for a total of 35,921 patient days. Among the medical wards we observed after the interruption a significant increase in fluoroquinolone use, with a change in trend (CT) of 0.996, = 0.027. In the surgical wards, we observed a significant increase in the overall consumption, with a change in level (CL) of 24.4, = 0.005, and in the use of third and fourth generation cephalosporins (CL 4.7, = 0.003). In two ICUs, we observed a significant increase in piperacillin/tazobactam and fluoroquinolone consumption (CT 9.28, = 0.019, and 2.4, = 0.047). In the wards with a duration of ASP less than 30 months, we observed a significant increase in antibiotic consumption in the use of piperacillin/tazobactam and fluoroquinolones (CT 12.9, = 0.022: 4.12, = 0.029; 1.004, = 0.011).

Conclusions: The interruption of ASP during COVID-19 led to an increase in the consumption of broad-spectrum antibiotics, particularly in surgical wards and in those with a duration of ASP less than 30 months.

Citing Articles

Determining the impact of the COVID-19 pandemic on the consumption of antibiotics in Shaanxi province, China: an interrupted time-series analysis.

Ji W, Zhao Y, Du J, Zhao H, McIver D, Ye D Front Public Health. 2025; 13:1475207.

PMID: 40046123 PMC: 11880026. DOI: 10.3389/fpubh.2025.1475207.


Global prevalence of human intestinal carriage of ESBL-producing during and after the COVID-19 pandemic.

Ng R, Yang L, Lau S, Hawkey P, Ip M JAC Antimicrob Resist. 2025; 7(1):dlaf001.

PMID: 39866328 PMC: 11759295. DOI: 10.1093/jacamr/dlaf001.


The Impact of SARS-CoV-2 Pandemic on Antibiotic Prescriptions and Resistance in a University Hospital from Romania.

Zaha D, Ilea C, Dorobantu F, Pantis C, Pop O, Dascal D Antibiotics (Basel). 2024; 13(6).

PMID: 38927144 PMC: 11200525. DOI: 10.3390/antibiotics13060477.


Impact of COVID-19 on antimicrobial stewardship activities in Italy: a region-wide assessment.

Vicentini C, Corcione S, Moro G, Mara A, De Rosa F, Zotti C Antimicrob Resist Infect Control. 2024; 13(1):48.

PMID: 38725026 PMC: 11084085. DOI: 10.1186/s13756-024-01407-3.


Analysis of Changes in Antibiotic Use Patterns in Korean Hospitals during the COVID-19 Pandemic.

Kim B, Hwang H, Chae J, Kim Y, Kim D Antibiotics (Basel). 2023; 12(2).

PMID: 36830109 PMC: 9952207. DOI: 10.3390/antibiotics12020198.


References
1.
Langford B, So M, Raybardhan S, Leung V, Soucy J, Westwood D . Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021; 27(4):520-531. PMC: 7785281. DOI: 10.1016/j.cmi.2020.12.018. View

2.
Riccardo F, Ajelli M, Andrianou X, Bella A, Del Manso M, Fabiani M . Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020. Euro Surveill. 2020; 25(49). PMC: 7730489. DOI: 10.2807/1560-7917.ES.2020.25.49.2000790. View

3.
Pitiriga V, Vrioni G, Saroglou G, Tsakris A . The Impact of Antibiotic Stewardship Programs in Combating Quinolone Resistance: A Systematic Review and Recommendations for More Efficient Interventions. Adv Ther. 2017; 34(4):854-865. DOI: 10.1007/s12325-017-0514-y. View

4.
Monnet D, Harbarth S . Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?. Euro Surveill. 2020; 25(45). PMC: 7667630. DOI: 10.2807/1560-7917.ES.2020.25.45.2001886. View

5.
Rawson T, Moore L, Castro-Sanchez E, Charani E, Davies F, Satta G . COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020; 75(7):1681-1684. PMC: 7314000. DOI: 10.1093/jac/dkaa194. View